A SEVERE CASE OF BUPROPION HYDROCHLORIDE EXTENDED-RELEASE MONOTHERAPY- ASSOCIATED VISUAL HALLUCINATIONS AND DELIRIUM IN A FEMALE PATIENT WITH MAJOR DEPRESSIVE DISORDER

被引:0
|
作者
Pae, Chi-Un [1 ,2 ]
机构
[1] Catholic Univ, Korea Coll Med, Bucheon St Marys Hosp, Dept Psychiat, Puchon 420717, Kyeonggi Do, South Korea
[2] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC USA
关键词
D O I
10.1017/S1092852900000596
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
引用
收藏
页码:601 / 602
页数:2
相关论文
共 11 条
  • [1] The role of extended-release quetiapine fumarate monotherapy in the treatment of patients with major depressive disorder
    Weisler, Richard
    McIntyre, Roger S.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2013, 13 (11) : 1161 - 1182
  • [2] Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder
    Hewett, K.
    Chrzanowski, W.
    Jokinen, R.
    Felgentreff, R.
    Shrivastava, R. K.
    Gee, M. D.
    Wightman, D. S.
    O'Leary, M. C.
    Millen, L. S.
    Leon, M. C.
    Briggs, M. A.
    Krishen, A.
    Modell, J. G.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (04) : 521 - 529
  • [3] An Open-Label, Rater-Blinded, 8-Week Trial of Bupropion Hydrochloride Extended-Release in Patients with Major Depressive Disorder with Atypical Features
    Seo, H. -J.
    Lee, B. C.
    Seok, J. -H.
    Jeon, H. J.
    Paik, J. -W.
    Kim, W.
    Kwak, K. -P.
    Han, C.
    Lee, K. -U.
    Pae, C. -U.
    PHARMACOPSYCHIATRY, 2013, 46 (06) : 221 - 226
  • [4] Efficacy of adjunct quetiapine extended-release in major depressive disorder: a pooled analysis of SSRI and SNRI patient subgroups
    Bauer, M.
    Demyttenaere, K.
    El-Khalili, N.
    Thase, M.
    Papakostas, G. I.
    Szamosi, J.
    Earley, W.
    Eriksson, H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S441 - S442
  • [5] Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial
    Shen Yifeng
    Zhao Qian
    Yu Yimin
    Tan Yunlong
    Zhang Honggeng
    Xu Xiufeng
    Wang Zhiyang
    Li Yan
    Hu Jingqiu
    Zhong Jinhua
    Li Huafang
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 257 : 143 - 149
  • [6] Desvenlafaxine extended-release tablets in major depressive disorder and menopause-associated hot flushes: a profile of its use
    Scott L.J.
    Drugs & Therapy Perspectives, 2017, 33 (10) : 449 - 454
  • [7] A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder
    Wang, Gang
    McIntyre, Alexander
    Earley, Willie R.
    Raines, Shane R.
    Eriksson, Hans
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 : 201 - 216
  • [8] Extended-release quetiapine fumarate (quetiapine XR) monotherapy and quetiapine XR or lithium as add-on to antidepressants in patients with treatment-resistant major depressive disorder
    Bauer, Michael
    Dell'Osso, Liliana
    Kasper, Siegfried
    Pitchot, William
    Vansvik, Eva Dencker
    Koehler, Juergen
    Jorgensen, Leif
    Montgomery, Stuart A.
    JOURNAL OF AFFECTIVE DISORDERS, 2013, 151 (01) : 209 - 219
  • [9] Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: Findings from a randomized, double-blind, placebo-controlled study
    Jefferson, James W.
    Rush, A. John
    Nelson, J. Craig
    VanMeter, Susan A.
    Kyishen, Alok
    Hampton, Kenneth D.
    Wightman, Donna S.
    Modell, Jack G.
    JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (06) : 865 - 873
  • [10] Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
    Sambunaris, Angelo
    Gommoll, Carl
    Chen, Changzheng
    Greenberg, William M.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (04) : 197 - 205